Trinity Biotech Partners with University at Buffalo to Develop Sjogren's Syndrome Biomarkers
Trinity Biotech announced it has entered into a collaboration agreement with the University at Buffalo, New York, or UB. The partnership focuses on advancing and commercializing a suite of proprietary biomarkers for the earlier and more accurate detection of Sjogren's Syndrome, one of the most common but underdiagnosed autoimmune diseases. Sjogren's Syndrome is a chronic, systemic autoimmune disease that primarily affects moisture producing glands in the eyes and mouth, with potential progressive involvement of multiple organ systems. The disease may affect the nervous system, lungs, and kidneys as well as the function of most other exocrine glands in the human body. Chronic fatigue, joint pain, and neuropathic pain are significant sources of disability. It is widely underdiagnosed and often mistaken for other autoimmune or inflammatory conditions. Under the collaboration agreement Trinity Biotech will codevelop and commercialize proprietary biomarkers discovered by UB faculty researchers and licensed to Trinity Biotech subsidiary IMMCO through Business and Entrepreneur Partnership's Technology Transfer Office, which manages UB's intellectual property and facilitates collaborations between UB faculty researchers and industry partners. Trinity Biotech expects the collaboration to generate multiple downstream benefits, including expanded clinical partnerships, enhanced payer relevant data packages, and a strengthened platform for future biomarker commercialization.
